Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).

Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB, Schrump DS, Shin DM, Walsh GL, Roth JA
Cancer Gene Ther. 2000 7 (4): 530-6

PMID: 10811470 · DOI:10.1038/sj.cgt.7700138

The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte proliferation and neutralizing antibody (Ab) formation were to adenovirus serotype 5 vector antigens, with increased responses in posttreatment samples. Consistent alterations in posttreatment cellular and humoral immune responses to p53 epitopes were not observed, and cytotoxic Abs to human lung cancer cells were not generated. Patients in this study had evidence of an antitumoral effect of this treatment with prolonged tumor stability or regression; however, neither Abs to p53 protein nor increased lymphocyte proliferative responses to wild-type or mutant p53 peptides have been consistently detected.

MeSH Terms (19)

Adenoviridae Aged Amino Acid Sequence Antibody Formation Carcinoma, Non-Small-Cell Lung Cytotoxicity, Immunologic Female Genetic Therapy Genetic Vectors Gene Transfer Techniques Humans Immunity, Cellular Lung Neoplasms Lymphocyte Activation Male Middle Aged Molecular Sequence Data Peptide Fragments Tumor Suppressor Protein p53

Connections (2)

This publication is referenced by other Labnodes entities:

Links